{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:00:34Z","timestamp":1793383234927,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib\/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010052","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T15:14:07Z","timestamp":1688138047000},"page":"5304-5313","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy\u2013treated mantle cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1451-0699","authenticated-orcid":false,"given":"Anna","family":"Nikkarinen","sequence":"first","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-8076","authenticated-orcid":false,"given":"Lavanya","family":"Lokhande","sequence":"additional","affiliation":[{"name":"2Department of Immunotechnology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-5252","authenticated-orcid":false,"given":"Rose-Marie","family":"Amini","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"4Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-2713","authenticated-orcid":false,"given":"Anna","family":"Porwit","sequence":"additional","affiliation":[{"name":"4Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Molin","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Enblad","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Innlandet Hospital Trust Division Gj\u00f8vik, Lillehammer, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"7Department of Haematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8231-8183","authenticated-orcid":false,"given":"Caroline E.","family":"Weibull","sequence":"additional","affiliation":[{"name":"8Division of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-5681","authenticated-orcid":false,"given":"Peter","family":"Hollander","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1388-4912","authenticated-orcid":false,"given":"Sara","family":"Ek","sequence":"additional","affiliation":[{"name":"2Department of Immunotechnology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden"},{"name":"8Division of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"issue":"5","key":"2023092213345603500_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"2023092213345603500_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"2023092213345603500_bib3","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"issue":"24","key":"2023092213345603500_bib4","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","article-title":"Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res"},{"issue":"13","key":"2023092213345603500_bib5","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.3390\/cancers14133229","article-title":"Tumor microenvironment and immunotherapy-based approaches in mantle cell lymphoma","volume":"14","author":"Saleh","year":"2022","journal-title":"Cancers"},{"issue":"21","key":"2023092213345603500_bib6","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/cancers14215318","article-title":"Artificial intelligence predicted overall survival and classified mature B-cell neoplasms based on immuno-oncology and immune checkpoint panels","volume":"14","author":"Carreras","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2023092213345603500_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.17366","article-title":"Infiltration of CD163-PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors","volume":"193","author":"Rodrigues","year":"2021","journal-title":"Br J Haematol"},{"key":"2023092213345603500_bib8","doi-asserted-by":"crossref","first-page":"701492","DOI":"10.3389\/fonc.2021.701492","article-title":"High counts of CD68+ and CD163+ macrophages in mantle cell lymphoma are associated with inferior prognosis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"16","key":"2023092213345603500_bib9","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2023092213345603500_bib10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jha2.549","article-title":"Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis","volume":"3","author":"Le Bris","year":"2022","journal-title":"EJHaem"},{"issue":"14","key":"2023092213345603500_bib11","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/bloodadvances.2020003871","article-title":"Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis","volume":"5","author":"Le","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"2023092213345603500_bib12","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.3390\/ijms21155497","article-title":"Targeting of CD163(+) macrophages in inflammatory and malignant diseases","volume":"21","author":"Skytthe","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2023092213345603500_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers14010141","article-title":"Approaches of the innate immune system to ameliorate adaptive immunotherapy for B-cell non-Hodgkin lymphoma in their microenvironment","volume":"14","author":"Watanabe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2023092213345603500_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365513.2011.626868","article-title":"Soluble CD163","volume":"72(1)","author":"M\u00f8ller","year":"2012","journal-title":"Scand J Clin Lab Invest"},{"issue":"17","key":"2023092213345603500_bib15","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1089\/ars.2012.4834","article-title":"CD163 and inflammation: biological, diagnostic, and therapeutic aspects","volume":"18","author":"Etzerodt","year":"2013","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"2023092213345603500_bib16","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.3892\/ol.2017.6547","article-title":"Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer","volume":"14","author":"Ding","year":"2017","journal-title":"Oncol Lett"},{"issue":"4","key":"2023092213345603500_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000349892","article-title":"Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer","volume":"75","author":"No","year":"2013","journal-title":"Gynecol Obstet Invest"},{"issue":"4","key":"2023092213345603500_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jhep.2013.06.008","article-title":"Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma","volume":"59","author":"Waidmann","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"2023092213345603500_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-022-03266-6","article-title":"Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma","volume":"72","author":"Lauridsen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"2023092213345603500_bib20","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.3390\/ijms21165925","article-title":"CD163 as a biomarker in colorectal cancer: the expression on circulating monocytes and tumor-associated macrophages, and the soluble form in the blood","volume":"21","author":"Krijgsman","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2023092213345603500_bib21","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3324\/haematol.2020.278182","article-title":"Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma","volume":"106","author":"Vajavaara","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2023092213345603500_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2023092213345603500_bib23","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3109\/10428194.2015.1026899","article-title":"Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia","volume":"56","author":"Nederby","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023092213345603500_bib24","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023092213345603500_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.17023","article-title":"p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma","volume":"191","author":"Rodrigues","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2023092213345603500_bib26","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package 'dagitty'","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"16","key":"2023092213345603500_bib27","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2018-08-870915","article-title":"Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study","volume":"133","author":"Hsi","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2023092213345603500_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2014.113472","article-title":"Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial","volume":"100","author":"Riihijarvi","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2023092213345603500_bib29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.14317","article-title":"Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC","volume":"175","author":"Plattel","year":"2016","journal-title":"Br J Haematol"},{"issue":"25","key":"2023092213345603500_bib30","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1182\/blood.2021014007","article-title":"Extracellular vesicles and PDL1 suppress macrophages inducing therapy resistance in TP53-deficient B-cell malignancies","volume":"139","author":"Izquierdo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023092213345603500_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12032-022-01732-w","article-title":"Secretome of senescent hepatoma cells modulate immune cell fate by macrophage polarization and neutrophil extracellular traps formation","volume":"39","author":"Sen","year":"2022","journal-title":"Med Oncol"},{"issue":"8","key":"2023092213345603500_bib32","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3390\/cancers12082303","article-title":"Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by ibrutinib via inhibition of JAK2","volume":"12","author":"Barbarino","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2023092213345603500_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023092213345603500_bib34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5304\/2080153\/blooda_adv-2023-010052-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5304\/2080153\/blooda_adv-2023-010052-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T13:35:35Z","timestamp":1695389735000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/18\/5304\/496623\/Soluble-CD163-predicts-outcome-in-both"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":34,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010052","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}